JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 16, 2007; DOI: 10.1124/jpet.107.129049


0022-3565/08/3241-72-78$20.00
JPET 324:72-78, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.129049v1
324/1/72    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, J.
Right arrow Articles by Abdel-Rahman, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, J.
Right arrow Articles by Abdel-Rahman, A. A.

CARDIOVASCULAR

Inhibition of Nischarin Expression Attenuates Rilmenidine-Evoked Hypotension and Phosphorylated Extracellular Signal-Regulated Kinase 1/2 Production in the Rostral Ventrolateral Medulla of Rats

Jian Zhang, and Abdel A. Abdel-Rahman

Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, North Carolina

Imidazoline (I1)-evoked hypotension is linked to enhanced phosphorylated extracellular signal-regulated kinase (pERK)1/2 production in the rostral ventrolateral medulla (RVLM). Recent cell culture findings suggest that nischarin is a candidate for the I1 receptor. In the present study, nischarin antisense oligodeoxynucleotide (ODN) (AS1 or AS2), designed according to nischarin cDNA sequence, was administered intracisternally (i.c., 2 nmol/rat for 2 days) to knockdown central nischarin expression; control rats received the corresponding mismatched ODN (MM1 or MM2) or artificial cerebrospinal fluid (aCSF). We investigated the effects of AS1 or AS2 on nischarin expression in the RVLM, and on the hypotension and RVLM pERK1/2 production elicited by the I1-selective agonist rilmenidine (25 µg/rat i.c.). Compared with aCSF, the mismatched ODN (MM1 or MM2) had no significant effect on RVLM nischarin expression or the cardiovascular and cellular (RVLM pERK1/2) responses elicited by rilmenidine. However, either antisense ODN substantially (>80%) reduced nischarin expression in the RVLM (AS1/MM1, 3 ± 1 versus 32 ± 2 positive cells; AS2/MM2, 4 ± 1 versus 31 ± 2 positive cells) and abrogated rilmenidine (I1)-evoked hypotension (AS1/MM1, –4.1 ± 0.9 versus –10.8 ± 1.9 mm Hg; AS2/MM2, –2.1 ± 1.1 versus –15.3 ± 2.5 mm Hg) and ERK1/2 activation in the RVLM (AS1/MM1, 10 ± 1 versus 15 ± 2 positive cells; AS2/MM2, 9 ± 1 versus 18 ± 2 positive cells). Finally, pERK1/2 generated by central I1 receptor activation is colocalized with nischarin in the RVLM neurons. This is the first evidence in vivo that nischarin plays a critical role in I1 receptor-mediated pERK1/2 production in the RVLM and the subsequent hypotension.


Received July 20, 2007; accepted October 15, 2007.

Address correspondence to: Dr. Abdel A. Abdel-Rahman, Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, NC 27834. E-mail: abdelrahmana{at}ecu.edu




This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
Y. Ding, T. Milosavljevic, and S. K. Alahari
Nischarin Inhibits LIM Kinase To Regulate Cofilin Phosphorylation and Cell Invasion
Mol. Cell. Biol., June 1, 2008; 28(11): 3742 - 3756.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.